Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Community Bank of Raymore
Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Community Bank of Raymore
Community Bank of Raymore grew its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 152.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,660 shares of the biopharmaceutical company's stock after purchasing an additional 9,460 shares during the quarter. Community Bank of Raymore's holdings in Bristol-Myers Squibb were worth $1,127,000 as of its most recent filing with the SEC.
根據該公司最近在與 SEC 提交的 13F 文件中，雷莫爾社區銀行在第四季度增長了 152.6％ 在布里斯多邁施貴寶（紐約證券交易所代碼：BMY-獲得評級）的股份。機構投資者在本季度額外購買 9,460 股股票後，擁有該生物製藥公司股票的 15,660 股股份。瑞莫爾社區銀行在百時美施貴寶的持股價值為 1,127,000 美元，截至最近在 SEC 提交的文件中。
A number of other institutional investors have also modified their holdings of the stock. Xponance Inc. raised its stake in Bristol-Myers Squibb by 28.0% during the third quarter. Xponance Inc. now owns 219,534 shares of the biopharmaceutical company's stock worth $15,607,000 after acquiring an additional 47,993 shares during the period. Grimes & Company Inc. raised its stake in Bristol-Myers Squibb by 1.6% during the third quarter. Grimes & Company Inc. now owns 295,464 shares of the biopharmaceutical company's stock worth $21,005,000 after acquiring an additional 4,778 shares during the period. Cliftonlarsonallen Wealth Advisors LLC raised its stake in Bristol-Myers Squibb by 2.2% during the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 12,366 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 261 shares during the period. Advocate Group LLC raised its stake in Bristol-Myers Squibb by 9.0% during the third quarter. Advocate Group LLC now owns 97,286 shares of the biopharmaceutical company's stock worth $6,916,000 after acquiring an additional 7,998 shares during the period. Finally, Columbia Asset Management acquired a new stake in Bristol-Myers Squibb during the second quarter worth about $495,000. Institutional investors and hedge funds own 75.51% of the company's stock.
不少其他機構投資者亦修改其持有的股票。Xponance 公司在第三季度提高了其在百時美施貴寶的股份 28.0％。在此期間額外收購 47,993 股股份後，Xponance 公司現在擁有該生物製藥公司股票的 219,534 股股票，價值 15,607,000 美元。格林斯公司在第三季度提高了其在百時邁施貴寶的股份 1.6％。在此期間，格萊姆斯公司現在擁有該生物製藥公司股票的 295,464 股股份，價值 21,005,000 美元。克里夫頓拉索納倫財富顧問有限責任公司提出了其在百時邁施貴寶的股份 2.2% 在第三季度.克里夫頓拉索納倫財富顧問有限責任公司現在擁有 12,366 股的生物製藥公司的股票價值 $879,000 在此期間收購的額外 261 股票後，股票.倡導集團有限責任公司在第三季度提高了其在百時美施貴寶的股份 9.0%.在此期間，倡導集團有限責任公司現在擁有該生物製藥公司股票的 97,286 股，價值 6,916,000 美元。最後，哥倫比亞資產管理公司在第二季度收購了百時美施貴寶的新股份，價值約為 495,000 美元。機構投資者和對沖基金擁有公司股票的 75.51％。
Insiders Place Their Bets
內部人士下注
In other news, EVP Ann Powell sold 11,183 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares in the company, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ann Powell sold 11,183 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares in the company, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Giovanni Caforio sold 240,000 shares of the firm's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now owns 236,104 shares in the company, valued at approximately $17,625,163.60. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.
在其他消息中，執行副總裁安·鮑威爾（Ann Powell）在 2 月 6 日（週一）的一項交易中出售了該公司股票的 11,183 股。這些股份以 74.69 美元的平均價格出售，交易總額為 835,258.27 美元。交易完成後，執行副總裁現擁有該公司 23,043 股股份，價值約為 1,721,081.67 美元。該交易在與證券交易委員會的法律文件中披露，可以通過以下方式訪問 證券交易所網站。在其他消息中，執行副總裁安·鮑威爾（Ann Powell）在 2 月 6 日（週一）的一項交易中出售了該公司股票的 11,183 股。這些股份以 74.69 美元的平均價格出售，交易總額為 835,258.27 美元。交易完成後，執行副總裁現擁有該公司 23,043 股股份，價值約為 1,721,081.67 美元。該交易在與證券交易委員會的法律文件中披露，可以通過以下方式訪問 證券交易所網站。此外，首席執行官喬瓦尼·卡福里奧在 2 月 6 日（星期一）的一次交易中出售了該公司股票的 240,000 股。這些股票以 74.65 美元的平均價格出售，總交易額為 17,916 萬美元。交易後，首席執行官現擁有該公司的 236,104 股股份，價值約為 17,625,163.60 美元。可以找到此次銷售的披露 這裡。業內人士擁有公司股票的 0.09%。
Bristol-Myers Squibb Trading Up 1.4 %
百時美施貴寶交易升 1.4%
Bristol-Myers Squibb stock traded up $0.97 during midday trading on Friday, reaching $69.17. The stock had a trading volume of 2,738,663 shares, compared to its average volume of 8,082,146. The firm's fifty day simple moving average is $70.16 and its two-hundred day simple moving average is $72.82. Bristol-Myers Squibb has a twelve month low of $65.28 and a twelve month high of $81.43. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The firm has a market cap of $145.49 billion, a price-to-earnings ratio of 23.12, a PEG ratio of 1.48 and a beta of 0.46.
百時美施貴寶股票在周五中午交易期間上漲 0.97 美元，達到 69.17 美元。該股的交易量為 2,738,663 股，與其平均成交量為 8,082,146 股相比。該公司的五十天簡單移動平均線為 70.16 美元，其 200 日簡單移動平均線為 72.82 美元。百時美施貴寶擁有十二個月低點 65.28 美元，十二個月高點為 81.43 美元。該公司的債務與權益比率為 1.13，流動比率為 1.25，快速比率為 1.14。該公司的市值為 145.49 億美元，股價與收益比率為 23.12，掛鉤比率為 1.48，測試值為 0.46。
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The company had revenue of $11.41 billion during the quarter, compared to the consensus estimate of $11.20 billion. During the same quarter in the prior year, the firm earned $1.83 EPS. The company's revenue was down 4.8% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb will post 8.06 EPS for the current fiscal year.
百時美施貴寶 (紐約證券交易所代碼:BMY — 獲得評級) 最後一次公布其收益業績，日期為 2 月 2 日（星期四）。這家生物製藥公司報告了本季度的每股盈利 1.82 美元，頂級分析師的共識估計為 1.71 美元，通過 0.11 美元。百時美施貴寶的淨利潤率為 13.71%，股本回報率為 51.60%。該公司在本季度的營收為 1141 億美元，而共識估計為 1120 億美元。在上一年同一季度，該公司的每股收益為 1.83 美元。與去年同期相比，該公司的收入下降了 4.8%。股票分析師預計百時美施貴寶將在本會計年度錄得 8.06 股盈餘。
Bristol-Myers Squibb Announces Dividend
百時美施貴寶宣佈股息
The business also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be given a $0.57 dividend. The ex-dividend date of this dividend is Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a yield of 3.30%. Bristol-Myers Squibb's payout ratio is 77.29%.
該業務最近還宣布了季度股息，將於 5 月 1 日（星期一）支付。4 月 10 日（星期一）有記錄的股東將獲得 0.57 美元的股息。該股息的除息日期為 4 月 6 日（星期四）。這代表按年化基礎計算 2.28 美元的股息，收益率為 3.30％。百時美施貴寶的支付比率為 77.29%。
Analyst Upgrades and Downgrades
分析師升級和降級
Several equities research analysts have commented on BMY shares. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "underweight" rating in a research note on Friday, February 3rd. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 3rd. Jefferies Financial Group started coverage on shares of Bristol-Myers Squibb in a research note on Monday, March 6th. They issued a "hold" rating and a $62.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, January 17th. They issued an "overweight" rating and a $95.00 price target on the stock. Finally, StockNews.com started coverage on shares of Bristol-Myers Squibb in a report on Thursday, March 16th. They issued a "strong-buy" rating for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $79.69.
幾位股票研究分析師對 BMY 股票發表了評論。摩根士丹利將百時美施貴寶股份的價格目標從 60.00 美元提高至 62.00 美元，並在 2 月 3 日（星期五）的一份研究報告中給予該公司「體重過輕」評級。富國銀行公司將百時美施貴寶股份的價格目標從 70.00 美元提高到 78.00 美元，並在 1 月 3 日（星期二）的一份研究報告中給予該公司「同等權重」評級。富瑞金融集團於 3 月 6 日（星期一）在一份研究報告中開始對百時美施貴寶的股份進行報導。他們發布了「持有」評級和 62.00 美元的股票價格目標。坎托·菲茨杰拉德開始覆蓋百時邁施貴寶的股份在研究筆記上週二, 1 月 17 日.他們發布了「超重」評級和 95.00 美元的股票價格目標。最後, Stocknews.com 開始覆蓋百時美施貴寶的股份在週四的報告, 3 月 16 日.他們為公司頒發了「強買」評級。一位股票研究分析師對該股票進行了賣出評級，七人發出了持有評級，七名已發出買入評級，其中一名為該股指定了強大的買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為「中等購買」，平均價格目標為 79.69 美元。
Bristol-Myers Squibb Profile
百時美施貴寶檔案
(Get Rating)
(取得評分)
Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
布里斯托爾邁爾斯 Squibb 公司從事生物製藥產品的發現，開發，許可，製造，營銷，分銷和銷售。它提供化學合成的藥物或小分子和產品從稱為生物製劑的生物過程產生.該公司成立於 1933 年 8 月，總部位於紐約州紐約。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
- 獲取有關百時美施貴寶（BMY）的股票新聞網研究報告
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze, 公司準備火箭更高?
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
- 沃爾瑪股票跳躍在 Evercore 分析師升級
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接收百時美施貴寶日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收百時美施貴寶及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。